Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics
Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics
复制标题
DOI：
10.1089/ten.2005.11.1198
复制
发表时间：
2005-07-01
影响因子：
--
通讯作者：
Caplan, AI
中科院分区：
文献类型：
--
作者：
Caplan, AI
成体干细胞提供替代和修复后代正常周转或损伤组织。这些细胞已经在培养中分离和扩增，它们用于治疗策略需要的技术尚未完善。在20世纪70年代，鸡胚肢芽间充质细胞培养系统提供了软骨、骨和肌肉分化的数据。在20世纪80年代，我们使用这种肢体芽细胞系统作为纯化骨诱导因子的实验。在20世纪90年代，我们利用在胚胎间充质祖细胞培养中获得的专业知识，开发了分离、扩增和保存成体骨髓来源间充质干细胞（MSCs）干细胞能力的技术。20世纪90年代，我们进入了组织工程的新领域，在那里，我们使用MSCs与特定部位的递送载体来修复软骨、骨、肌腱、骨髓基质、肌肉和其他结缔组织。在21世纪初，我们已经取得了实质性的进展：最重要的是一种被称为“绘画”的细胞涂层技术的发展，它使我们能够将信息蛋白质引入细胞的外表面。这些涂料可以作为靶向地址，专门对接MSCs或其他修复细胞到独特的组织地址。科学和临床挑战仍然存在：完善基于细胞的组织工程方案，通过外科植入支架、生物活性因子和修复细胞来再生受损或患病的骨骼组织，利用人体自身的再生能力。
Adult stem cells provide replacement and repair descendants for normal turnover or injured tissues. These cells have been isolated and expanded in culture, and their use for therapeutic strategies requires technologies not yet perfected. In the 1970s, the embryonic chick limb bud mesenchymal cell culture system provided data on the differentiation of cartilage, bone, and muscle. In the 1980s, we used this limb bud cell system as an assay for the purification of inductive factors in bone. In the 1990s, we used the expertise gained with embryonic mesenchymal progenitor cells in culture to develop the technology for isolating, expanding, and preserving the stem cell capacity of adult bone marrow- derived mesenchymal stem cells ( MSCs). The 1990s brought us into the new field of tissue engineering, where we used MSCs with site- specific delivery vehicles to repair cartilage, bone, tendon, marrow stroma, muscle, and other connective tissues. In the beginning of the 21st century, we have made substantial advances: the most important is the development of a cell- coating technology, called painting, that allows us to introduce informational proteins to the outer surface of cells. These paints can serve as targeting addresses to specifically dock MSCs or other reparative cells to unique tissue addresses. The scientific and clinical challenge remains: to perfect cell- based tissue- engineering protocols to utilize the body's own rejuvenation capabilities by managing surgical implantations of scaffolds, bioactive factors, and reparative cells to regenerate damaged or diseased skeletal tissues.